Desmopressin: Safety considerations in patients with chronic renal disease

Drug Safety

Volumn 29, Issue 7, 2006, Pages 553-556

  Sica, Domenic A ^a   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; DESMOPRESSIN; HEMOSTATIC AGENT; METFORMIN; VASOPRESSIN;

ARTERIAL PRESSURE; BLEEDING TENDENCY; CHRONIC KIDNEY DISEASE; DIABETES INSIPIDUS; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG LABELING; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEMOPHILIA A; HUMAN; HYPONATREMIA; LACTIC ACIDOSIS; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PULSE RATE; SIDE EFFECT; TACHYPHYLAXIS; THROMBOCYTE ANOMALY; URINE INCONTINENCE; VON WILLEBRAND DISEASE;

ANTIDIURETIC AGENTS; DEAMINO ARGININE VASOPRESSIN; HEMOSTATICS; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 33746788464     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629070-00001     Document Type: Editorial

References (25)

1. Kim RJ, Malattia C, Allen M, et al. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev 2004; 2 Suppl. 1: 115-23
2. Wolfish NM, Barkin J, Gorodzinsky F, et al. The Canadian Enuresis Study and Evaluation: short- and long-term safety and efficacy of an oral desmopressin preparation. Scand J Urol Nephrol 2003; 37: 22-7
3. Johnson II TM, Miller M, Tang T, et al. Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study. J Am Med Dir Assoc 2006; 7: 6-11
4. Manucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12
5. Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's diseases. Lancet 1977; I: 869-72
6. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-9
7. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-53
8. Remuzzi G. Bleeding in renal failure. Lancet 1988; I: 1205-8
9. Escolar G, Diaz-Ricart M, Cases A. Uremic platelet dysfunction: past and present. Curr Hematol Rep 2005; 4: 359-67
10. Sohal AS, Gangji AS, Crowther MA, et al. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 2005, [epub ahead of print]
11. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93
12. Canavese C, Salomone M, Pacitti A, et al. Reduced response of uraemic bleeding time to repeated doses of desmopressin. Lancet 1985; I: 867-8
13. Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus nighttime in healthy men aged 55-70 years. Eur J Clin Pharmacol 2004; 60: 397-402
14. Fjellestad-Paulsen A, Hoglund P, Lundin S, et al. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 1993; 38: 177-82
15. Ruzicka H, Bjorkman S, Lethagen S, et al. Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. Pharmacol Toxicol 2003; 92: 137-42
16. Agerso H, Seiding Larsen L, Riis A, et al. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 2004; 58: 352-8
17. Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6: 11-4
18. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006; 25: 105-9
19. Callreus T, Ekman E, Andersen M. Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of case series. Eur J Clin Pharmacol 2005; 61: 281-4
20. Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989; 114: 470-2
21. Package Insert. Desmopressin acetate (DDAVP®). Aventis Pharmaceuticals Inc. Bridgewater (NJ)
22. Package Insert. Metformin (Glucophage®). Bristol-Myers Squibb Inc. Princeton (NJ)
23. Package Insert. Dofetilide (Tikosyn®). Pfizer Pharmaceuticals Inc. New York (NY)
24. Package Insert. Sotalol hydrochloride (Betapace®). Berlex Laboratories Inc. Wayne (NJ)
25. Ulusoy S, Ovali E, Aydin F, et al. Hemostatic and fibrinolytic response to nasal desmopressin in hemodialysis patients. Med Princ Pract 2004; 13: 340-5